SCHEMBL4848906

SCHEMBL4848906

Nc1ccc(CO)cc1Nc1cc(Cl)ccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
DNM2 P50570 1/20 0.44
GRIK1 P39086 8/20 0.44
GAA P10253 1/20 0.43
KCNH2 Q12809 1/20 0.43
RAB9A P51151 1/20 0.43
P2RY4 P51582 1/20 0.43
P2RY12 Q9H244 1/20 0.43
USP2 O75604 1/20 0.42
PABPC1 P11940 1/20 0.42
CDC25B P30305 1/20 0.41
CASP6 P55212 1/20 0.41
RCE1 Q9Y256 1/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854787 0.90 MEN1 (0.47) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1290925 0.81 GRIK1 (0.54) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL11603313 0.80 GRIK1 (0.62) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1366625 0.79 CDC25B (0.56) MEN1KMT2AGRIK1USP2CDC25B
SCHEMBL4855385 0.77 ABL1 (0.56) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL4858225 0.77 ABL1 (0.52) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL4857424 0.76 MEN1 (0.45) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL10872978 0.75 GRIK1 (0.48) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL11604096 0.74 KDM4E (0.60) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL10720962 0.73 GRIK1 (0.46) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 EP disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 MEN1 1677/4885KMT2A 1398/4885ALDH1A1 2391/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 MEN1 2238/4885KMT2A 1376/4885ALDH1A1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.